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Specific circulating microRNAs 
during hepatitis E infection can 
serve as indicator for chronic 
hepatitis E
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Lina Hanisch1, Jens Kurreck  6, Jörg Hofmann7,8 & C.-Thomas Bock  1,9*
Hepatitis E virus (HEV) genotypes 3 and 4 (HEV-3, HEV-4) infections are an emerging public health issue 
in industrialized countries. HEV-3 and −4 are usually self-limiting but can progress to chronic hepatitis 
E in immunocompromised individuals. The molecular mechanisms involved in persistent infections are 
poorly understood. Micro RNAs (miRNAs) can regulate viral pathogenesis and can serve as novel disease 
biomarkers. We aimed to explore the modulation of serum miRNAs in patients with acute (AHE) and 
chronic (CHE) hepatitis E. Both AHE- and CHE-patients exhibited high viral loads (median 3.23E + 05 IU/
mL and 2.11E + 06 IU/mL, respectively) with HEV-3c being the predominant HEV-genotype. Expression 
analysis of liver-specific serum miRNAs was performed using real-time PCR. miR-99a-5p, miR-122-5p, 
and miR-125b-5p were upregulated in AHE (4.70–5.28 fold) and CHE patients (2.28–6.34 fold), 
compared to HEV-negative controls. Notably, miR-192-5p was increased 2.57 fold while miR-125b-5p 
was decreased 0.35 fold in CHE but not in AHE patients. Furthermore, decreased miR-122-5p expression 
significantly correlates with reduced liver transaminases in CHE patients. To our knowledge, this marks 
the first investigation concerning the regulation of circulating liver-specific miRNAs in acute and chronic 
HEV infections. We found that miR-125b-5p, miR-192-5p, and miR-99a-5p may prove useful in the 
diagnosis of chronic hepatitis E.
Hepatitis E virus (HEV) is attributed to an estimated 20 million cases of acute viral hepatitis worldwide with 
44,000 deaths each year, mainly occurring during large waterborne outbreaks of genotypes 1 and 2 (HEV-1, 
HEV-2)1. The fecal-orally transmitted HEV-1 and -2 are highly endemic in resource limited regions, such as 
Africa, India and Asia. Meanwhile, the number of reported autochthonous infections with HEV genotypes 3 and 
4 (HEV-3, HEV-4) has risen exponentially over the last decade and hepatitis E is now recognized as an emerging 
disease in developed countries and a significant health burden1–4.
Infections in immunocompetent patients usually remain asymptomatic or present as a mild and self-limiting 
viral hepatitis without lasting damage. Serious complications such as fulminant hepatic failure can occur in 
patients with pre-existing liver disease while increased fetal and maternal mortality rates are reported in infected 
pregnant women5,6. Persistent infections can manifest in immunocompromised individuals including solid organ 
and hematopoietic stem cell transplant patients, leading to adverse clinical outcomes7–9. Viral RNA detectable in 
patient blood for a time period exceeding three months is considered indicative of chronic hepatitis E (CHE)10. 
The current off-label treatment option for CHE include the nucleoside analogue ribavirin but is often accom-
panied by clinical side effects11. In addition, evidence suggests that ribavirin may promote selection of viral 
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quasi-species associated with treatment failure and viral recurrence12–14. The earliest detection of a persistent 
HEV infection is paramount to the advancement of successful antiviral treatment. In light of this, novel biomark-
ers for this emerging infectious disease need to be discovered and characterized.
Micro RNAs (miRNAs) are evolutionarily conserved ~21–25 nucleotide long single-stranded non-coding 
RNA molecules15. miRNAs are posttranscriptional regulators of gene expression through complementary bind-
ing to the 5′ or 3′UTR of target mRNA molecules16. More than 60% of human genes are predicted to be targets 
for endogenous miRNAs while a number of miRNAs are capable of targeting several mRNAs17. Consequently, 
miRNAs are involved in the regulation of numerous biological processes ranging from cell proliferation and 
apoptosis, tissue development and differentiation and immune responses18.
Several miRNA species have been found to be dysregulated in various diseases. The fact that tissue-specific 
miRNAs may enter the blood stream has opened up the possibility of using circulating miRNAs as non-invasive 
predictors of disease progression and treatment outcome19,20. Previous studies have investigated the modulation 
of miRNA levels in the setting of liver diseases such as drug- and alcohol-induced liver injury, as well as hepato-
cellular carcinoma21–23. However, miRNA expression is also affected by viral hepatitis like hepatitis B and hepatitis 
C. A number of miRNAs including miR-99a, miR-122, and miR-125b were found to be upregulated in patients 
with hepatitis B virus (HBV) infection and expression levels allowed differentiation between HBV, hepatitis C 
virus (HCV) and HBV-related hepatocellular carcinoma24–27. Additionally, circulating levels of miR-122, miR-
125b and miR-192 were increased in HBeAg-positive patients28. Increased serum miR-122 levels are predictive 
for enhanced inflammation in chronic HCV patients29,30.
Only little is known concerning miRNA regulation during acute and chronic HEV infection. In acute hepa-
titis E miR-122, -221 and -222 have been implicated to regulate HEV in vitro, and several miRNAs expressed in 
peripheral blood mononuclear cells including miR-431, -654, -1468, and -4435 were able to differentiate acute 
hepatitis E in pregnant and non-pregnant31–33. A recent study has shown that HEV-encoded miRNAs may dys-
regulate host cell pathways during infection34. However, data of miRNA regulation in chronic hepatitis E are still 
missing. Therefore, we aimed to explore and compare the miRNA signatures in serum of acute and chronic HEV 
infected patients to elucidate differences in miRNA regulation which potentially may lead to chronic hepatitis E.
Materials and Methods
Patient samples. In total, 38 patient serum samples were included. Six samples were collected from patients 
presenting with acute hepatitis E infection (AHE) and viremia (AHEv), four from AHE patients without viremia 
(AHEnv). Twelve samples were from renal transplant patients suffering from chronic hepatitis E infection (CHE) 
with viremia (CHEv) and six from CHE patients without detectable HEV viral load (CHEnv) after ribavirin 
(RBV) treatment. Finally, ten samples from HEV sero- and RNA-negative renal transplant patients served as a 
control group (control). Inclusion criteria for AHE patients were detectable anti-HEV IgM antibodies and HEV 
RNA in blood (AHEv) or undetectable RNA (AHEnv), respectively. CHEv patients were tested positive for anti-
HEV IgG and IgM and detectable HEV RNA in blood for more than three months. CHEv patients were tested 
retrospectively for HEV RNA up to two years prior to first detection by RT-PCR using stored serum samples. 
CHEnv patients had detectable anti-HEV IgG and IgM titers but were negative for HEV RNA in blood. Where 
applicable, patients were additionally tested for serum alanine (ALT) and aspartate transaminase (AST) levels.
Molecular characterization of HEV. Viral RNA was extracted from 140 µl of serum using QIACube and 
the QIAamp Viral RNA Mini kit (Qiagen, Hilden, Germany) according to the manufacturer´s instructions. Viral 
loads were determined by HEV-specific real-time quantitative RT-PCR and HEV geno- and subtypes were deter-
mined by nested RT-PCR followed by Sanger sequencing and phylogenetic analysis using partial ORF1 and ORF2 
sequences as previously described35,36.
Profiling of circulating miRNAs. In order to evaluate miRNA expression levels and profiles of AHE, CHE 
groups, and HEV-negative control group, analysis of 180 miRNA species was performed using miRCURY LNA 
Universal cDNA Synthesis Kit II (Exiqon, Vedbaek, Denmark) for reverse transcription, ExiLENT SYBR Green 
master mix (Exiqon, Vedbaek, Denmark) for quantitative PCR (qPCR) amplification and Serum/Plasma Focus 
qPCR Panels V4.RO (Exiqon, Vedbaek, Denmark) according to the manufacturer´s instructions. As internal 
amplification controls synthetic miRNAs UniSp2, 4 and 5 were added as spike-ins before extraction and UniSp6 
before cDNA synthesis (Exiqon, Vedbaek, Denmark). Data analysis was performed with GenEx qPCR analysis 
software (Exiqon, Vedbaek, Denmark). Raw cycle threshold (Ct) values were inter-plate calibrated using UniSp3. 
To identify endogenous reference miRNAs and regulated miRNAs for expression analyses during HEV infection, 
global mean normalization was performed. In brief, fold changes (FC) of miRNA expression in AHE and CHE 
patients compared to controls were calculated using the 2−ΔΔCt method. Four regulated miRNAs were selected 
for further investigation based on previous studies24–30. The three most stably expressed miRNAs were selected as 
endogenous reference genes.
Evaluation of miRNA profiles. Four regulated liver-specific miRNAs (miR-99a-5p, miR-122-5p, miR-
125b-5p, miR-192-5p) and three potential reference miRNAs (let-7a-5p, let-7b-5p, miR-126-3p) were chosen for 
validation using miRNA-specific qPCR based on initial serum miRNA profiling. Expression levels of miRNAs 
of the panel were analyzed from 38 serum samples of 6 AHEv-, 4 AHEnv-, 12 CHEv-, 6 CHEnv-patients and 10 
non-infected control patients.
Circulating miRNAs were extracted from 200 µl serum using the miRNeasy Serum/Plasma Advanced Kit 
(Qiagen, Hilden, Germany) following the manufacturer’s instructions. RNA was reverse transcribed using miR-
CURY LNA RT kit (Qiagen, Hilden, Germany) following the protocol for 10 µl reactions using 1 µl of RNA. 
Expression analysis via miRNA-specific qPCR was performed using 2x miRCURY SYBR Green Master Mix 
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(Qiagen, Hilden, Germany) and miRCURY LNA miRNA Custom 96 well PCR Panels (Qiagen, Hilden, Germany) 
on a Roche LightCycler 480 II instrument (Roche Diagnostics GmbH, Mannheim, Germany) according to manu-
facturer instructions. Non-template controls (NTC) were used to assess background fluorescence and reasonable 
cut-off values for expression analysis.
Statistical analysis. Raw Ct values were calculated using absolute quantification and uploaded to the Qiagen 
GeneGlobe Data Analysis online tool (https://www.qiagen.com/us/shop/analytics-software/biological-data-tools/
geneglobe-data-analysis-center/). A cut-off of Ct = 36 was chosen to ensure inclusion of only robustly amplified 
samples based on non-template control values.
Three potential endogenous reference miRNAs (let-7a-5p, let-7b-5p, miR-126-3p) were evaluated based on 
the premise that the ratio of expression of two true reference miRNAs is identical across all patient groups37. 
ΔCt values were calculated using the average of the two most stable reference miRNAs and fold changes of each 
regulated miRNA species determined via the 2−ΔΔCt method. Statistical analyses were performed with standard 
deviations of ΔΔCt values using unpaired, two-tailed Student’s t-test with p-values below 0.05 considered as 
statistically significant.
Scatter plots, ROC, AUC and correlation analysis were designed using GraphPad Prism v8.1.2 (GraphPad 
Software, Inc., San Diego, USA). Receiver operating characteristic (ROC) was applied to test predictive per-
formance of liver-specific miRNAs. ROC area under curve (AUC) was calculated by DeLong method. Optimal 
cut-off values were determined by Youden’s index (Supplementary Tables S2 and S3). Pearson correlation coeffi-
cient was calculated for correlation analysis of miR-122-5p and ALT/AST levels. Two-tailed p-values were calcu-
lated. P-values below 0.05 were considered to indicate statistical significance.
Ethical approval. The local ethics committee of the Charité Universitätsmedizin Berlin approved the 
study (approval number No. EA1/367/16) and written informed consent was obtained. Patient samples were 
de-identified for this study. All experiments were performed in accordance with relevant guidelines and 
regulations.
Results
Patient characteristics and determination of HEV infection. All 38 patient samples included were 
analyzed for virus load and (sub)genotype using HEV-specific real-time qPCR and nested RT-PCR followed by 
Sanger sequencing and phylogenetic analyses. AHEv and CHEv serum samples were found to be viremic with a 
median viral load of 3.23E + 05 IU/ml serum (1.44E + 04 to 8.15E + 06 IU/ml) and 2.11E + 06 IU/ml (1.29E + 04 
to 7.27E + 06 IU/ml), respectively. Phylogenetic analyses showed that all HEV-positive samples were HEV gen-
otype 3. 5/6 AHEv and 9/12 CHEv clustered within HEV subtype 3c while one AHEv and one CHEv sample 
belonged to subtype 3e. The remaining two CHEv samples clustered within subtype 3b and 3f, respectively. Patient 
details with clinical and virological characteristics are summarized in Table 1.
9/12 CHEv patients had increased transaminase levels (defined as >35 IU/ml), whereas only 1/6 CHEnv and 
1/10 HEV-negative control patients had moderately increased ALT/AST levels. Transaminase levels determined 
in 5/6 AHEv patients showed increased ALT/AST values. Similarly, all AHEnv patients for which transaminase 
levels were available (3/4) exhibited increased ALT/AST levels (Table 1).
Identification of regulated miRNAs. A preliminary miRNA expression profiling of 180 common circulat-
ing miRNAs using Serum/Plasma Focus qPCR Panels V4.RO was performed with miRNAs isolated from serum 
of a AHEv, AHEnv, CHEv, CHEnv and non-HEV renal transplant control patient, respectively (Supplementary 
Table S1). Regulation of expression levels of miRNAs in HEV-positive samples compared to the control group 
was observed for liver-specific miRNAs. From these, miR-99a-5p, miR-122-5p, miR-125b-5p and miR-192-5p 
were chosen for validation based on their involvement in HBV and HCV described in previous studies24–30. Three 
none or only minor regulated miRNAs (let-7a-5p, let-7b-5p and miR-126-3p) among all tested miRNAs in AHEv, 
AHEnv, CHEv and CHEnv when compared to non-HEV controls were selected to validate their use as endoge-
nous reference miRNAs in HEV infection.
let-7a-5p and let-7b-5p serve as serum reference miRNAs in HEV infection. To evaluate the three 
candidate reference genes identified in the preliminary miRNA profiling, their expression ratios were analyzed. 
Normalization was carried out with each of the three potential reference miRNAs. Fold changes (FCs) compared 
to HEV-negative controls were calculated for each data set. When let-7a-5p was used for normalization, let-
7b-5p expression exhibited stable expression among AHEnv (FC = 0.99), CHEv (FC = 0.93), CHEnv (FC = 0.97) 
and AHEv (FC = 0.77) patients. Conversely, normalization with let-7b-5p resulted in stable expression of let-
7a-5p among AHEnv (FC = 1.01), CHEv (FC = 1.08), CHEnv (FC = 1.04) and AHEv (FC = 1.30) patients as well 
(Table 2). Let-7a-5p and let-7b-5p thereby possessed the most stable expression ratios among the three tested 
miRNAs in AHEnv, CHEv and CHEnv serum samples and thereby proved to be the most optimal candidates 
serving as endogenous reference genes in HEV infection.
Liver-specific miRNAs are differentially regulated in acute and chronic HEV infections. Initial 
analyses revealed that miR-99a-5p, miR-122-5p, miR-125b-5p and miR-192-5p were most promising candidates 
to differentiate between acute and chronic hepatitis E by miRNA signatures. To further analyze these candidate 
miRNAs, detailed expression analyses were conducted on serum miRNAs from AHEv, AHEnv, CHEv, CHEnv 
and non-HEV controls.
Expression of candidate miRNAs was normalized using the mean Ct of let-7a and let-7b. Plotted mean ΔCt 
values with 95% confidence intervals of the 4 target miRNAs are depicted in Fig. 1.
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Expression of liver-specific serum miRNAs in AHE and CHE was first compared to the non-infected control 
group (Table 3). MiR-99a-5p showed strongest regulation in serum of AHEv with a fold change (FC) of 4.74 
(p-value = 0.014) compared to the control group followed by CHEv with FC of 2.69 (p-value < 0.001). Similarly, 
miR-125b-5p showed highest expression in serum of AHEv and CHEv with FCs of 4.70 (p-value = 0.004) and 
2.28 (p-value = 0.006), respectively. Serum expression of miR-122-5p was increased 6.34-fold (p-value = 0.008) 
in CHEv and 5.28-fold (p-value = 0.038) in AHEv compared to the control. Additionally, CHEv patients exhib-
ited a 2.57-fold increase (p-value < 0.001) of serum miR-192-5p. Although no statistically significant regulation 
of the mean expression of investigated serum miRNAs was observed in AHEnv and CHEv when compared to the 
control group, a subset of AHEnv patients retained increased levels of miR-122-5p (p-value = 0.219).
Next, expression of the candidate miRNAs in chronic HEV group was compared to acute HEV group (Table 4). 
Lower expression levels of miR-125b-5p were observed when comparing CHEv and CHEnv to AHEv with FCs of 
0.48 (p-value = 0.024) and 0.35 (p-value = 0.043), respectively. In addition, a subset of CHEnv patients had lower 
serum levels of miR-99a-5p (FC = 0.27, p-value = 0.067), miR-122-5p (FC = 0.23, p-value = 0.096) and miR-






































N/A +/+ 8.15E + 06
3.23E + 05
3c
DE/18–0223 F 78 0 52/58 +/+ 3.55E + 05 3c
DE/18–0224 M 54 0 1417/383 −/+ 2.91E + 05 3c
DE/18–0225 F 37 0 54/44 +/+ 4.57E + 05 3e
DE/18–0226 M 46 0 155/131 +/+ 2.36E + 05 3c










DE/18–0219 F 33 — 121/41 +/+ — N/A
DE/18–0220 M 56 — N/A +/+ — N/A







29/29 +/+ 9.41E + 05
2.11E + 06
3c
DE/16–0013 M 46 810 285/121 +/+ 3.22E + 06 3f
DE/16–0014 M 54 673 85/56 +/+ 5.96E + 05 3e
DE/16–0015 F 34 1314 21/19 +/+ 2.91E + 06 3c
DE/16–0017 M 25 401 116/36 +/+ 6.63E + 05 3c
DE/16–0018 M 56 561 212/96 +/+ 1.79E + 06 3c
DE/16–0019 M 52 91 159/88 +/+ 2.16E + 06 3c
DE/16–0020 M 54 848 62/44 +/+ 4.20E + 06 3c
DE/16–0022 M 57 926 62/52 +/+ 2.07E + 06 3b
DE/16–0023 F 60 282 32/37 +/+ 4.70E + 06 3c
DE/16–0024 M 76 791 57/62 +/+ 1.29E + 04 3c










DE/18–0228 M 47 1010 16/27 +/+ — N/A
DE/18–0229 M 58 1015 34/27 +/+ — N/A
DE/18–0230 F 61 539 11/17 +/+ — N/A
DE/18–0232 M 56 722 21/23 +/+ — N/A










DE/18–0235 M 68 — 9/23 −/− — N/A
DE/18–0236 F 47 — 17/21 −/− — N/A
DE/18–0237 F 57 — 16/17 −/− — N/A
DE/18–0238 M 67 — 22/22 −/− — N/A
DE/18–0239 M 50 — 21/18 −/− — N/A
DE/18–0240 M 62 — 28/28 −/− — N/A
DE/18–0241 F 58 — 16/25 −/− — N/A
DE/18–0242 M 59 — 25/23 −/− — N/A
DE/18–0243 F 58 — 109/42 −/− — N/A
Table 1. Clinical and virological characteristics of HEV-positive patients and HEV-negative controls. 
N/A = not applicable; ∅ = median; y = years, d = days; ALT/AST = transaminases, AHEv = viremic acute; 
AHEnv = non-viremic acute; CHEv = viremic chronic; CHEnv = non-viremic chronic.
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No significant miRNA regulation was observed in CHEv and CHEnv when compared to AHEnv, however, miR-
192-5p was downregulated in a subset of CHEnv patients (FC = 0.37, p-value = 0.071) while a subset of CHEv 
patients demonstrated increased miR-122-5p levels (FC = 2.99, p-value = 0.160).
AHEv AHEnv CHEv CHEnv
Fold changes after normalization with let-7a-5p
miRNA FC p-value FC p-value FC p-value FC p-value
let-7b-5p 0.77 0.138 0.99 0.816 0.93 0.705 0.97 0.656
miR-126-3p 2.06 <0.001 2.00 <0.001 1.61 0.043 2.00 <0.001
AHEv AHEnv CHEv CHEnv
Fold changes after normalization with let-7b-5p
miRNA FC p-value FC p-value FC p-value FC p-value
let-7a-5p 1.30 0.130 1.01 0.922 1.08 0.524 1.04 0.961
miR-126-3p 2.67 <0.001 2.02 0.003 1.73 0.016 2.07 <0.001
AHEv AHEnv CHEv CHEnv
Fold changes after normalization with let-7a-5p and let-7b-5p in combination
miRNA FC p-value FC p-value FC p-value FC p-value
let-7a-5p 1.14 0.124 1.01 0.990 1.04 0.562 1.02 0.878
let-7b-5p 0.88 0.127 0.99 0.875 0.96 0.656 0.98 0.722
miR-126-3p 2.34 <0.001 2.01 <0.001 1.67 0.019 2.03 <0.001
Table 2. Fold changes of potential endogenous serum reference miRNAs let-7a-5p and let-7b-5p in HEV 
patients compared to non-infected control group. FC = fold change; AHEv = viremic acute; AHEnv = non-
viremic acute; CHEv = viremic chronic; CHEnv = non-viremic chronic.
Figure 1. Scatter plot of ΔCt values of liver-specific miRNA in serum of AHE and CHE patients and control 
group depicted in scatter plots. Each dot represents one patient sample. Bars represent 95% confidence intervals 
of the mean. Statistically significant differences between patient groups depicted with asterisks (* < 0.05; ** < 
0.01; *** < 0.001) and determined using standard deviation of ΔΔCt values.
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Finally, differences in serum miRNA levels between viremic and non-viremic HEV patients were investigated 
(Table 5). While no statistically significant regulation in mean serum expression could be identified in AHEnv 
compared to AHEv patients, a subset of AHEnv patients demonstrated downregulated miR-99a-5p (FC = 0.37, 
p-value = 0.198), miR-122-5p (FC = 0.40, p-value = 0.278) and miR-125-p (FC = 0.36, p-value = 0.120) levels. 
However, compared to CHEv patients, CHEnv patients exhibited significantly decreased expression of serum 
miR-99a-5p, miR-122-5p and miR-192-5p with FCs of 0.47 (p-value = 0.007), 0.19 (p-value = 0.029) and 0.21 
(p-value < 0.001), respectively.
Statistical analyses on predictive performances of investigated liver-specific miRNAs in acute 
and chronic hepatitis E patients. The predictive value to distinguish between CHEv or AHEv and 
non-infected control patients of miR-99a-5p, miR-125b-5p and miR-192-5p was assessed. ROC AUC values were 
calculated from the curves to compare the performance of each miRNA in a singular test. In serum of AHEv 
patients, only miR-99a-5p (ROC AUC = 0.933; p-value = 0.005) and miR-125b-5p (ROC AUC = 0.950; p-value 
= 0.003) proved significant predictive performance. However, in CHEv patients miR-99a-5p (ROC AUC = 0.917; 
p-value = 0.001), miR-125b-5p (ROC AUC = 0.900; p-value = 0.002), as well as miR-192-5p (ROC AUC = 0.942; 
p-value < 0.001) demonstrated to be predictive for chronic HEV when compared to HEV-negative control 
patients (Table 6). These data are in accordance with miRNA regulation in AHEv and CHEv patients when com-
pared to control patients (Table 3). ROC curves of the investigated miRNAs in AHEv and CHEv patients are 
presented in Supplementary Fig. S4.
Correlation analysis of miR-122-5p expression in CHEv, CHEnv and non-infected control patients demon-
strated a significant correlation between reduced miR-122-5p expression and decreased levels of ALT (Pearson 
r = −0.552; p-value = 0.002), as well as AST (Pearson r = −0.580; p-value = 0.001) (Table 7) in serum of these 
groups. Graphs of correlation analysis can be found in Supplementary Fig. S5.
miRNA
AHEv AHEnv CHEv CHEnv
FC p-value FC p-value FC p-value FC p-value
miR-99a-5p 4.74 0.014 1.73 0.139 2.69 <0.001 1.27 0.600
miR-122-5p 5.28 0.038 2.12 0.219 6.34 0.008 1.21 0.648
miR-125b-5p 4.70 0.004 1.70 0.136 2.28 0.006 1.66 0.118
miR-192-5p 1.42 0.127 1.48 0.130 2.57 <0.001 0.55 0.081
Table 3. Fold changes of liver-specific serum miRNAs in HEV patients compared to non-infected control 
group. FC = fold change; AHEv = viremic acute; AHEnv = non-viremic acute; CHEv = viremic chronic; 
CHEnv = non-viremic chronic.
miRNA
vs. AHEv vs. AHEnv
CHEv CHEnv CHEv CHEnv
FC p-value FC p-value FC p-value FC p-value
miR-99a-5p 0.57 0.049 0.27 0.067 1.55 0.290 0.74 0.295
miR-122-5p 1.20 0.806 0.23 0.096 2.99 0.160 0.57 0.091
miR-125b-5p 0.48 0.024 0.35 0.043 1.34 0.396 0.97 0.680
miR-192-5p 1.81 0.962 0.39 0.143 1.74 0.259 0.37 0.071
Table 4. Fold changes of liver-specific serum miRNAs in chronic HEV patients compared to acute HEV 
patients. FC = fold change; AHEv = viremic acute; AHEnv = non-viremic acute; CHEv = viremic chronic; 
CHEnv = non-viremic chronic.
miRNA
vs. AHEv AHEnv vs. CHEv CHEnv
FC p-value FC p-value
miR-99a-5p 0.37 0.198 0.47 0.007
miR-122-5p 0.40 0.278 0.19 0.029
miR-125b-5p 0.36 0.120 0.73 0.148
miR-192-5p 1.04 0.652 0.21 <0.001
Table 5. Fold changes of liver-specific serum miRNAs in viremic compared to non-viremic HEV patients. 
FC = fold change; AHEv = viremic acute; AHEnv = non-viremic acute; CHEv = viremic chronic; CHEnv = 
non-viremic chronic.
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Discussion
HEV infection is a major cause of acute hepatitis globally showing various clinical outcomes from asymptomatic 
courses to severe hepatitis. Chronic hepatitis E is recognized as a growing health issue in immunocompromised 
patients.
It is now recognized that renal transplant patients are at risk of developing chronic hepatitis E; however, the 
full spectrum of adverse effects is still unclear. A retrospective study in German renal transplant recipients deter-
mined a 1.1% (16 out of 1469) prevalence of chronic HEV and 16.3% prevalence among those patients with 
elevated liver enzymes (16 out of 98)8. As the time point of seroconversion of HEV is variable, molecular meth-
ods should be used to diagnose HEV infection8. However, neither serology nor nucleic acid detection have yet 
conclusively identified factors involved in development of chronicity or disease courses. In light of this, we aimed 
to determine regulated miRNAs in serum of patients with acute and chronic manifestations of HEV infection to 
elucidate differences and discover potential indicators of disease progression.
MiRNAs are known to modulate viral pathogenesis and are therefore involved in determining the course of 
infection. Our study marks the first investigation of the regulation of circulating miRNAs in patients with acute 
versus chronic hepatitis E, including viremic and non-viremic HEV infections.
All isolated HEV RNA from patient serum included in the study belonged to genotype 3, with subtype 3c 
being predominant. A previous study found no association between disease severity and HEV-3 subtypes and our 
findings further ensured exclusion of differences in serum miRNA expression occurring from HEV genotypes38. 
Furthermore, to our knowledge there are no documented pharmacological effects of immunosuppressive drugs 
on the expression of the hepatic miRNAs investigated in this work. Therefore, comparisons between miRNA 
profiles in acute and chronic hepatitis E patients are deemed valid.
Initial profiling of 180 serum miRNAs showed potential regulation of the liver-specific miRNAs miR-99a-5p, 
miR-122-5p, miR-125b-5p and miR-192-5p (suppl. Table S1). As only one patient sample per group was initially 
tested, discrepancies compared to the validation cohort can be explained by individual miRNA expression levels 
as it is evident from Fig. 1. However, validation of these candidates confirmed significant differences in miRNA 
expression profiles in serum of HEV infected patients (Tables 3–5). Although miRNA spike-ins were included 
during profiling, these do not reflect the mean circulating miRNA content or quality39,40. It has previously been 
suggested to screen for potential endogenous reference miRNAs based on their expression stability and then fur-
ther validate these41. Two of the three potential reference miRNAs identified during profiling, let-7a-5p and let-
7b-5p, showed comparable expression levels across all patient groups in the validation phase and thus were used 
for normalization of expression data (Table 2). Notably, let-7a-5p has also been identified as a reference miRNA 
in serum of liver carcinoma patients suggesting that its expression levels remain unaltered during liver disease42.
Changes in circulating miRNA signatures have been studied for different clinical manifestations in both HBV 
and HCV infected patients24–27,29,30. Our results revealed differences in serum miRNA regulation between HEV 
infected and non-HEV patients, as well as acute and chronic, patients (Tables 3–5). Particularly, the combination 
of miR-99a-5p, -122-5p and -125b-5p for AHEv and miR-99a-5p, -122-5p, -125b-5p and -192-5p for CHEv may 
be used to differentiate acute from chronic infections when comparing to non-HEV controls (Table 3).
When comparing AHE and CHE (Table 4), miRNA expression levels of miR-125-5p showed a signif-
icant decrease in CHEv and CHEnv if compared to AHEv. Additionally, miR-99a-5p was decreased in 




AUC SEM 95% CI [%] p-value Sensitivity Specificity
CHEv
miR-99-5p 0.917 0.068 0.783–1.051 0.001 83.3% 80%
miR-125-5p 0.900 0.076 0.751–1.049 0.002 83.3% 80%
miR-192-5p 0.942 0.048 0.848–1.036 <0.001 75% 80%
AHEv
miR-99-5p 0.933 0.069 0.799–1.068 0.005 100% 90%
miR-125-5p 0.950 0.055 0.842–1.058 0.003 100% 90%
miR-192-5p 0.517 0.179 0.167–0.867 0.914 50% 0%
Table 6. Predictive values of miR-99a-5p, miR-125b-5p and miR-192-5p in AHEv and CHEv patients 
compared to non-infected control group as calculated by ROC analysis. AHEv = viremic acute; CHEv = 
viremic chronic; ROC AUC = receiver operating characteristic area under curve; SEM = standard error of 
mean; CI = confidence interval; Sensitivity and specificity are given for fixed values of 90% specificity and 90% 
sensitivity, respectively.
∆Ct miR-122-5p vs. ALT/AST
Parameter Pearson r 95% CI [%] p-value
ALT −0.552 (−0.767)–(−0.220) 0.002
AST −0.580 (−0.784)–(−0.260) 0.001
Table 7. Correlation analysis of serum miR-122-5p expression and ALT/AST levels in CHE and non-infected 
control patients. ALT = alanine transaminase; AST = aspartate transaminase; CHE = chronic hepatitis E; 
CI = confidence interval.
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miR-125b-5p and miR-99a-5p may be among those miRNAs whose expressions are altered during chronic infec-
tion. However, to specify whether transplant patients have lower levels of miR-99a-5p and miR-125b-5p as well 
as higher levels of miR-192-5p than non-transplanted acute patients at onset of the HEV infection or if these 
changes occur after transition of acute to persistent infection requires further examination in a larger AHE and 
CHE cohort. Additionally, miRNA profiles during acute and chronic phases within the same patient should be 
investigated in more detail in further experiments. However, these experiments were not possible in this analysis 
due to the limited number of available samples.
In addition, miR-122-5p expression is increased in CHEv patients compared to HEV-negative renal transplant 
controls (FC = 6.34, p-value = 0.008), whereas CHEnv patients showed comparable expression levels to control 
patients (FC = 1.21, p-value = 0.648). Previous reports have shown that increased miR-122-5p serum levels could 
be associated with various liver injuries and are considered as potential biomarkers43,44. As 9/12 CHEv patients 
had increased transaminase levels at time of sample collection, compared to only 1/6 CHEnv and 0/10 non-HEV 
renal transplant control patients, a correlation between increased miR-122-5p expression and liver injury appears 
obvious. Indeed, correlation analysis on miR-122-5p expression and ALT/AST levels in these patient groups 
confirm a significant correlation of these clinical parameters. This finding merits further investigation in a larger 
patient cohort.
The role of the investigated miRNAs during HEV infection remains unclear, however hypotheses based on the 
reported functions of miR-99a-5p, -122-5p, -125b-5p and -192-5p can be made. Common described functional 
activity of these miRNAs is the maintenance of hepatic differentiation and function, as well as suppression of cell 
proliferation and apoptosis45–50. Additionally, involvement of miR-122-5p in viral replication is demonstrated 
by its stabilization of the HCV genome and subsequent enhancement of replication51. Notably, a recent in vitro 
study has shown a similar effect of miR-122-3p on HEV replication32. As 3p and 5p forms are processed from 
a common pre-miRNA, the 3p form may be retained in the liver during HEV infection to promote replication 
while the 5p form is sequestered into the serum. HEV may profit from increased hepatic cell maintenance and 
decreased apoptosis, allowing lasting intrahepatic replication as well as from a possible pro-viral role of miR-122. 
However, such potential mechanisms must be confirmed using liver tissue from hepatitis E patients or suitable 
in vitro models.
In conclusion, this study marks the initial report of miRNA signatures determined in serum from acute and 
chronic hepatitis E virus infected patients. It is to our knowledge the first description of let-7a-5p and let-7b-5p as 
reference miRNAs for use in HEV serum studies. The regulated miRNAs miR-99a-5p, miR-122-5p, miR-125b-5p 
and miR-192-5p are not only important in the liver setting but share functional properties such as suppression 
of cell proliferation as well as apoptosis and may possibly play pro-viral roles in HEV replication. In our observa-
tion, miR-192-5p expression with accompanied viral load in blood may differentiate between acute and chronic 
stages of HEV infection compared to non-HEV patients. In addition, miR-125-5p and miR-99a-5p may serve as 
additional indicators to differentiate between acute viremic and persistent HEV infection. The predictive value of 
these three miRNAs were analyzed using ROC curves and found to be significant with miR-192-5p expression in 
particular being able to differentiate acute (ROC AUC = 0.517; p-value = 0.914) and chronic (ROC AUC = 0.942; 
p-value < 0.001) phases of HEV infection (Table 6). We further observed a significant correlation of miR-122-5p 
and transaminase levels (ALT/AST) in CHE and HEV-negative renal transplant control patients. Further studies 
are needed to pinpoint the temporal modulation of miRNA expression during transition from acute to chronic 
hepatitis E. The differentiation between acute and chronic infection at the earliest time point is crucial for fast and 
effective patient management and it is undeniable that miRNAs, as a class of emerging and non-invasive biomark-
ers, will play a leading role in future diagnostics.
Data availability
All data generated or analysed during this study are included in this article and in the supplementary material.
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